Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.52
-0.28 (-3.18%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Immix Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 79.25 | 93.93 | 17.68 | 17.51 | 13.44 | 17.64 |
Short-Term Investments | 11.33 | 6.48 | - | - | - | - |
Cash & Short-Term Investments | 90.58 | 100.41 | 17.68 | 17.51 | 13.44 | 17.64 |
Cash Growth | 468.93% | 467.86% | 0.98% | 30.31% | -23.85% | 4411.66% |
Other Receivables | - | - | 1.97 | 1.17 | 0.26 | 0.03 |
Total Trade Receivables | - | - | 1.97 | 1.17 | 0.26 | 0.03 |
Other Current Assets | 1.7 | 0.83 | 0.54 | 1.11 | 1.21 | 0.52 |
Total Current Assets | 92.27 | 101.24 | 20.2 | 19.79 | 14.9 | 18.19 |
Net Property, Plant & Equipment | 3.36 | 3.49 | 2.73 | 0.05 | 0 | 0.01 |
Other Long-Term Assets | 0.19 | 0.11 | 0.02 | 0.09 | 0.01 | - |
Total Assets | 95.82 | 104.84 | 22.95 | 19.93 | 14.91 | 18.19 |
Accounts Payable | 10.41 | 9.97 | 8.62 | 3.72 | 1.27 | 0.14 |
Accrued Expenses | - | - | - | - | - | 0.01 |
Short-Term Debt | - | - | - | - | - | 0.05 |
Current Portion of Leases | 0.13 | 0.14 | 0.07 | - | - | - |
Total Current Liabilities | 10.54 | 10.11 | 8.69 | 3.72 | 1.27 | 0.2 |
Long-Term Leases | 0.91 | 0.93 | 1.01 | - | - | - |
Other Long-Term Liabilities | - | - | - | - | 0.48 | - |
Total Long-Term Liabilities | 0.91 | 0.93 | 1.01 | - | 0.48 | - |
Total Liabilities | 11.45 | 11.04 | 9.7 | 3.72 | 1.75 | 0.2 |
Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
Treasury Stock | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | - |
Additional Paid-in Capital | 198.9 | 198.29 | 88.37 | 69.78 | 51.16 | 47.62 |
Accumulated Other Comprehensive Income | 0.11 | 0.06 | -0 | 0.13 | 0.09 | 0.13 |
Retained Earnings | -114.55 | -104.46 | -75.02 | -53.41 | -37.99 | -29.76 |
Total Common Shareholders' Equity | 84.36 | 93.8 | 13.25 | 16.41 | 13.16 | 17.99 |
Minority Interest | - | - | - | -0.2 | - | - |
Shareholders' Equity | 84.36 | 93.8 | 13.25 | 16.2 | 13.16 | 17.99 |
Total Liabilities & Equity | 95.82 | 104.84 | 22.95 | 19.93 | 14.91 | 18.19 |
Total Debt | 1.04 | 1.07 | 1.07 | 0 | 0 | 0.05 |
Net Cash (Debt) | 89.54 | 99.34 | 16.61 | 17.51 | 13.44 | 17.59 |
Net Cash Growth | 502.48% | 498.15% | -5.16% | 30.31% | -23.63% | - |
Net Cash Per Share | 2.27 | 3.01 | 0.59 | 1.01 | 0.97 | 4.79 |
Book Value | 84.36 | 93.8 | 13.25 | 16.41 | 13.16 | 17.99 |
Book Value Per Share | 2.14 | 2.85 | 0.47 | 0.95 | 0.95 | 4.90 |
Tangible Book Value | 84.36 | 93.8 | 13.25 | 16.41 | 13.16 | 17.99 |
Tangible Book Value Per Share | 2.14 | 2.85 | 0.47 | 0.95 | 0.95 | 4.90 |